尧唐（上海）生物科技有限公司 Mediaroom - PR Newswire APAC

Search

尧唐（上海）生物科技有限公司

Latest News

YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pio...

2025-09-11 20:05 1799

YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH)

SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company...

2025-06-06 11:52 1874

YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia

SHANGHAI, April 28, 2025 /PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gen...

2025-04-28 13:22 2214

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing...

2025-02-25 16:15 1819

YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia

SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company...

2025-01-21 10:34 2921

YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ...

2024-12-21 16:23 4179

YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland China

SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene edit...

2024-08-27 18:30 1728

YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1

SHANGHAI, Aug. 22, 2024 /PRNewswire/ -- YolTech Therapeutics, a pioneering clinical-stage gene edit...

2024-08-22 18:00 2259

First Patient Dosed in Phase I Clinical Trial of YOLT-201

SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo ...

2024-07-11 20:11 2218

YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China

Strategic Partnership to Advance Gene Editing Technologies in Biomedical Applications SHANGHAI, Ju...

2024-06-19 09:00 2164

First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH

SHANGHAI, April 2, 2024 /PRNewswire/ -- YolTech Therapeutics announced that the first patient has b...

2024-04-02 20:00 1907

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical com...

2024-03-27 20:00 1938

YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024

SHANGHAI, March 13, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company pioneering inin vi...

2024-03-13 20:00 2037

Landmark Clinical Approval for YOLT-201 Obtained by the NMPA

SHANGHAI, March 4, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo ...

2024-03-04 20:00 1159

YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developingin vivo ge...

2024-01-02 20:30 1879

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

SHANGHAI, Dec. 17, 2023 /PRNewswire/ -- YolTech Therapeutics today announced that the first patient...

2023-12-17 23:15 1916